27th Diabetes and Cardiovascular Risk Factors – East Meets West (EMW) Symposium

In patients with type 2 diabetes (T2D), empagliflozin 25 mg daily offers greater kidney protection than its 10 mg daily dose or dapagliflozin 10 mg daily, a retrospective cohort study in Hong Kong has shown.

At EmW 2025, Professor Andrea Luk from the Department of Medicine & Therapeutics, the Chinese University of Hong Kong, shared insights and recommendations on management of young-onset diabetes (YoD).